FROM OUTDATED TO UPDATED Eminence-Based Medicine
|
|
- Gerald Douglas Kennedy
- 5 years ago
- Views:
Transcription
1 FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4
2 CLINICAL TRIALS Help us to Better diagnose Guide special testing Make treatment decisions Educate patients 5 6 DIAGNOSIS TESTING DRS/ETDRS Anti-VEGF trials show benefit of testing Defined CSME and High Risk NV Find treatable macular edema 7 8
3 TREATMENT TREATMENT Many trials highlight effectiveness of treatment ONTT, HEDS Some may be counterintuitive CVOS 9 10 TREATMENT EDUCATION What to expect when treated Side effects 50% of ODs surveyed knew how to tx Herpes Simples Keratitis Outcomes Course of treatment Natural history 11 12
4 GOALS GOALS Diabetes Mellitus Understand Studies Learn what to look for in diagnosis Develop plan for referral/patient education AMD Glaucoma Herpes Simplex Optic Neuritis DIABETES MELLITUS DIABETES MELLITUS Threats to Vision Proliferative NVG Traction RD Threats to Vision Macula Edema Ischemia V-Heme 15 16
5 DIABETIC RETINOPATHY STUDY (DRS) DIABETIC RETINOPATHY STUDY Benefit found for High Risk NV Does PRP reduce the rate of profound vision loss from PDR Profound vision loss = < 20/800 NVD 1/4 Disc Area NVD or NVE with pre-retinal/v-heme If not high risk, not enough benefit to justify treatment DIABETIC RETINOPATHY STUDY DIABETIC RETINOPATHY STUDY Benefit = prevent profound vision loss Profound Vision Loss Risk = peripheral vision loss 10% develop macular edema 25% Untreated 12.5% Treated 50% Relative Risk Reduction 19 20
6 DIABETIC RETINOPATHY STUDY RISK REDUCTION Profound Vision Loss 12.5% Absolute Risk Reduction (ARR) ARR = Untreated - Treated NNT = 100/ARR Number Needed to Treat (NNT) = RISK REDUCTION RISK REDUCTION 50% Relative Risk Reduction 100% -> 50% 40% -> 20% 2/million -> 1/million 23 24
7 RISK REDUCTION EARLY TREATMENT DIABETIC RETINOPATHY STUDY (ETDRS) Does focal/grid laser help patients with diabetic macular edema? EARLY TREATMENT DIABETIC RETINOPATHY STUDY (ETDRS) Found benefit if Clinically Significant Macular Edema (CSME) Retinal thickening 1 disc area any part within 1 disc diameter of center of fovea Hard exudates within 1/3 disc diameter of center of fovea with adjacent thickening Retinal thickening within 1/3 disc diameter of center of fovea 27 28
8 EARLY TREATMENT DIABETIC RETINOPATHY STUDY (ETDRS) EARLY TREATMENT DIABETIC RETINOPATHY STUDY (ETDRS) If CSME If CSME Loss of < 2 lines 25% untreated ARR = 12.5% NNT = % treated DIABETIC MACULAR EDEMA STUDIES Treatment Criteria - Anti-VEGF Central retinal thickening <20/30 BOLT RESTORE RISE/RIDE DRCR 31 32
9 STUDIES STUDIES 100% lost < 3 lines with Avastin Compared to 86% with laser 40% gained > 3 lines with Lucentis Compared to 22% with laser (deferred Lucentis) STUDIES STUDIES 60% achieved 20/40 with Lucentis Compared to 42% with laser (deferred Lucentis) At 5 years Lucentis + Laser 75% achieved 20/
10 DRCR STUDIES 1% rate of endophthalmitis Could Eylea be given less frequently? 0.06% per injection rate (out of 3176 injections) VISTA/VIVID VISTA/VIVID Gain 3 lines 2 Year Results Aflibercept (Monthly or Bi-monthly) vs. Laser Monthly 38% Bi-monthly 33% Laser 13% Ophthalmology 2015;122:
11 VISTA/VIVID LUCENTIS FOR PDR Average injections Monthly - 22 Bi-monthly - 14 Is Lucentis as good as PRP for PDR? LUCENTIS FOR PDR LUCENTIS FOR PDR PRP group lost 3 letters Lucentis group lost no letters VF loss -23 db Lucentis -422 db PRP 43 44
12 LUCENTIS FOR PDR DME ANTI-VEGF - SUMMARY Lucentis and Avastin effective for DME Macular Edema 9% Lucentis 28% PRP 60-75% reading acuity at 5 years Can be combined with laser **10% developed macular edema with PRP in DRS DME ANTI-VEGF - SUMMARY DIABETIC RETINOPATHY Application Aflibercept may be given less often When can we stop? Treatment indicated if High risk PDR CSME Central macular thickening with < 20/
13 AGE-RELATED MACULAR DEGENERATION AGE-RELATED MACULAR DEGENERATION Threats to Vision Atrophy Threats to Vision Atrophy Neovascularization AGE-RELATED MACULAR DEGENERATION AGE-RELATED MACULAR DEGENERATION Threats to Vision Neovascularization Atrophic AREDS Exudative Anti-VEGF (Lucentis, Avastin, Eyelea) 51 52
14 AGE-RELATED MACULAR DEGENERATION AGE-RELATED EYE DISEASE STUDY (AREDS) Atrophic AREDS Exudative Are high-dose multivitamins with A, C, E, and Zinc able to reduce progression of dry AMD? Anti-VEGF (Lucentis, Avastin, Eyelea) AGE-RELATED EYE DISEASE STUDY (AREDS) AGE-RELATED EYE DISEASE STUDY (AREDS) 4 Categories No benefit found for Categories 1 and 2 1. No AMD - few small or no drusen 2. Early AMD - several small drusen or few medium sized 3. Intermediate AMD - many medium drusen or large drusen 4. Advanced AMD When Categories 3 and 4 were combined, benefit found Reduction of acuity of 3 lines 29% untreated 23% treated 55 56
15 AGE-RELATED EYE DISEASE STUDY (AREDS) AGE-RELATED EYE DISEASE STUDY (AREDS) Categories 3 and 4 No complications from vitamins found ARR 6% NNT = 17 Other trials have found Increased lung cancer in smokers on Vitamin A Increased prostate cancer with Zinc Worse heart disease with Vitamin E AGE-RELATED EYE DISEASE STUDY (AREDS) AGE-RELATED EYE DISEASE STUDY (AREDS) AREDS 10 year AREDS 2 found no difference between AREDS 1 by adding Lutein and Zeaxanthin Moderate vision loss 53% untreated 46% treated 59 60
16 AGE-RELATED EYE DISEASE STUDY (AREDS) AGE-RELATED EYE DISEASE STUDY (AREDS) AREDS 10 year AREDS 10 year Moderate vision loss ARR 7% NNT = 14 Still no benefit for Categories 1 and 2 Most benefit observed in Category 4 No benefit for Central Geographic Atrophy STUDIES - ANTI-VEGF STUDIES MARINA/ANCHOR VIEW CATT/GEFAL 90% maintain acuity with treatment Only 50% untreated maintain Treat and Extend 63 64
17 STUDIES STUDIES 41% gained 3 lines of acuity with treatment Only 6% untreated gained 33-42% achieve 20/40 or better treated Only 6% untreated reach 20/ STUDIES TREAT AND EXTEND Avastin = Lucentis = Eylea Fewer injections with Eylea 11 vs 16 at 2 years Treat every month for 3 months If stable, extend out 67 68
18 TREAT AND EXTEND TREAT AND EXTEND 90% had stability at 2 years 45% had 20/40 acuity Fewer injections (13 versus 17) Fewer Visits Less $$ Ophthalmology 2015;122: AMD GLAUCOMA Evidence from pre-glaucoma (OHTS) to advanced glaucoma (AGIS) Application Evidence for low tension (CNTGS) Evidence for surgery vs. medicine (CIGTS) Still no treatment for Dry AMD Vitamins can slow progression in small group of patients Wet AMD helped by Anti-VEGF Next frontier is less frequent administration 71 72
19 OCULAR HYPERTENSION TREATMENT STUDY (OHTS) OCULAR HYPERTENSION TREATMENT STUDY (OHTS) Evaluate the benefit of treating ocular hypertension to reduce development of glaucoma Patients with IOP Treated with medication to lower IOP to < 24 Minimum of 20% reduction OCULAR HYPERTENSION TREATMENT STUDY (OHTS) OCULAR HYPERTENSION TREATMENT STUDY (OHTS) Outcome Reproducible VF loss 9.5% untreated 4.4% treated Clinically significant optic disc deterioration 75 76
20 OCULAR HYPERTENSION TREATMENT STUDY (OHTS) OCULAR HYPERTENSION TREATMENT STUDY (OHTS) ARR 5.1% Application NNT = 20 We can prevent Glaucoma by treating Ocular Hypertension Most people with Ocular Hypertension don t develop Glaucoma OCULAR HYPERTENSION TREATMENT STUDY (OHTS) OCULAR HYPERTENSION TREATMENT STUDY (OHTS) What else did we learn? What else did we learn? 86% of patients with VF loss returned to normal after 1 repeat Patients with IOP with thinner corneas had higher risk Does this mean that all patients with thinner corneas are at risk?? 79 80
21 EARLY MANAGEMENT GLAUCOMA TRIAL (EMGT) EARLY MANAGEMENT GLAUCOMA TRIAL (EMGT) Determine benefit of treating patients with early Glaucoma Outcomes VF progression ONH progression EARLY MANAGEMENT GLAUCOMA TRIAL (EMGT) EARLY MANAGEMENT GLAUCOMA TRIAL (EMGT) 62% Untreated 45% Treated ARR 17% NNT =
22 EARLY MANAGEMENT GLAUCOMA TRIAL (EMGT) EARLY MANAGEMENT GLAUCOMA TRIAL (EMGT) What else did we find out? Application 50% of patients with VF loss reverted to normal upon retesting There is evidence that treating early glaucoma is beneficial COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY (CNTGS) COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY (CNTGS) Treatment goal = lowering IOP by 30% from baseline Establish whether there is a benefit to treating NTG with medication Measure VF progression ONH progression 87 88
23 COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY (CNTGS) COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY (CNTGS) Results If not fixation threatened, 2/3 did not progress COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY (CNTGS) COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY (CNTGS) Application Results If fixation threatened, should treat Of the 1/3 that did progress, added to fixation threatened group 12% treated progressed If non-fixation threatened, may be ok to watch carefully 35% untreated progressed 91 92
24 COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY (CIGTS) COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY (CIGTS) To evaluate whether patients do better with Trabeculectomy followed by medication Medication followed by trabeculectomy Outcomes VF progression VA loss IOP goal met COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY (CIGTS) COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY (CIGTS) Surgical complications 17% needed cataract surgery (compared to 6% of medicine group) No substantial difference in VF progression 13% flat AC 12% ptosis 11% risk of choroidal detachment 7% of surgical lost > 3 lines of acuity 4% in medicine arm 10% AC bleed 6% wound leak 1% hypotony 95 96
25 ADVANCED GLAUCOMA INTERVENTION STUDY (AGIS) ADVANCED GLAUCOMA INTERVENTION STUDY (AGIS) Evaluated benefit of treatment for patients with advanced Glaucoma Often stated outcomes deal with whether to do Trabeculectomy or Laser Trabeculoplasty first These results have little clinical application ADVANCED GLAUCOMA INTERVENTION STUDY (AGIS) GLAUCOMA Application Biggest messages are We can slow progression of even advanced glaucoma The lower the IOP the better <18 was good, <14 was even better No matter what stage, we can intervene with IOP lowering Medication and surgery are effective Medication is safer VF loss should be confirmed
26 HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) Herpes Ocular Complications Epithelial typically resolves without complication Epithelial Disease NO steroid! Stromal Disease Uveitis HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) Stromal is COMPLEX! Consider herpetic uveitis if Often worst outcomes Older age Triad Uveitis Corneal edema Increased IOP
27 HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) HEDS 1 When using topical antiviral, are topical steroids beneficial in treating stromal keratitis? HEDS 1 For patients with stromal keratitis, on topical steroid and anti-viral, is it beneficial to add oral acyclovir? More failure during first 10 weeks on placebo 73% vs 26% No statistically significant difference HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) HEDS 1 For patients with HSV uveitis, is there benefit to adding oral acyclovir? HEDS 2 Does oral acyclovir used early in treatment of acute HSV keratitis reduce risk of developing stromal keratitis or uveitis later? Not enough patients enrolled No
28 HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) HEDS 2 HEDS 2 Does low dose oral acyclovir reduce likelihood or recurrence? Does low dose oral acyclovir reduce likelihood or recurrence? Yes! 400 mg BID reduced from 32% to 19% HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) HEDS 2 HEDS helped inform us how to treat Herpes Simplex Does UV, stress, or corneal trauma influence recurrence rate? If epithelial disease, treat with topical antiviral No
29 HERPETIC EYE DISEASE STUDY (HEDS) HERPETIC EYE DISEASE STUDY (HEDS) If stromal, treat with topical steroid with antiviral cover If stromal with overlying epithelial defect, must treat epithelium first Consider oral antiviral for preventing recurrence HERPETIC EYE DISEASE STUDY (HEDS) OPTIC NEURITIS TREATMENT TRIAL (ONTT) Not enough patients to know for HSV uveitis Evaluated use of steroids in treating acute optic neuritis Consider if also have elevated IOP, corneal edema Consider if first uveitis in older patient
30 OPTIC NEURITIS OPTIC NEURITIS TREATMENT TRIAL (ONTT) Inflammation of optic nerve Patients randomized into 3 groups Consider in younger patients (20-40) Oral pred (1 mg/kg/day) x 14 days IV steroid x 3 days then oral pred x 11 days Oral placebo x 14 days OPTIC NEURITIS TREATMENT TRIAL (ONTT) OPTIC NEURITIS TREATMENT TRIAL (ONTT) For decades patients treated with Oral Steroid Based on Anecdote 93% of all patients recovered to at least 20/40 at 1 year ONTT sought to answer benefit
31 OPTIC NEURITIS TREATMENT TRIAL (ONTT) OPTIC NEURITIS TREATMENT TRIAL (ONTT) IV steroid with oral taper sped recovery 4 days compared to 15 days 1/3 of patients had recurrence Oral prednisone group had 44% recurrence rate OPTIC NEURITIS TREATMENT TRIAL (ONTT) OPTIC NEURITIS TREATMENT TRIAL (ONTT) At 15 years Oral prednisone group Did not improved visual acuity outcomes Increased rate of new attack of optic neuritis 69% were 20/20 Overall rate of developing MS was 50%
32 OPTIC NEURITIS TREATMENT TRIAL (ONTT) OPTIC NEURITIS TREATMENT TRIAL (ONTT) What else did we learn? At 15 years 90% of patients had pain on eye movement If no lesions on MRI, risk of MS was 25% If 1 or more MRI lesions, risk was 72% 1/3 of optic neuritis is papillitis 2/3 of optic neuritis is retrobulbar optic neuritis Look for APD OPTIC NEURITIS TREATMENT TRIAL (ONTT) Application Most patients with Optic Neuritis recover acuity Oral steroids don t help and might harm Consider MRI findings when educating about risk of MS Look for signs/symptoms Pain on eye movement, APD, possible ONH edema 127
8/8/17. Objectives. Proliferative Diabetic Retinopathy (PDR) Examining the Diabetic Patient: What Matters Most
Objectives Examining the Diabetic Patient: What Matters Most Jordan Keith, OD, FAAO Minneapolis, MN Simplify strategy for evaluating the eyes of diabetics Identify the threats to vision and treatments
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationMEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT
MEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT Hussein Hollands, MD, MS (epid) Peter J. Kertes, MD, CM, FRCS(C) 72 The purpose of
More informationCommon Causes of Vision Loss
Common Causes of Vision Loss Learning Objectives To identify the most common causes of vision loss in the United States To differentiate the most common forms of agerelated macular degeneration and diabetic
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationFrom Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014
From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationVanderbilt Eye Institute Clinical Trials
April, 2010 Vanderbilt Eye Institute Clinical Trials Ophthalmology Actively Recruiting Studies For information on our clinical trials and other studies, please contact: Sandy Owings, COA, CCRP Clinic Director
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationNew Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
More information1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures
Case Management Strategies in Diabetic Retinopathy Disclosures No financial conflict of interest Will discuss off label use of intraocular Bevacizumab (Avastin) for Diabetic Retinopathy Sundeep Dev, MD
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationDiabetic Retinopathy Update 2017
Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep
More informationMarcus Gonzales, OD, FAAO Cedar Springs Eye Clinic
Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic 25.6 million adults 11.3% of the adult population 10.9 million adults 65 years and older 26.9% of this age population 79 million people are Pre-diabetic!!
More informationAging & Ophthalmology
Aging & Ophthalmology Pr Jean-Marie Rakic Dr Denis Malaise January 2018 Major ocular diseases 1. Cataract 2. Age-related macular degeneration 3. Ischemic optic neuropathy 4. Horton arteritis 5. Glaucoma
More informationNote: This is an outcome measure and can be calculated solely using registry data.
Measure #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery -- National Quality Strategy Domain: Effective Clinical Care DESCRIPTION: Percentage of patients
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationOphthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors
More informationPast ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control
Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1
More informationDiabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the
More informationOutline. Preventing & Treating Diabetes Related Blindness. Eye Care Center Doctors. Justin Kanoff, MD. Eye Care Center of Northern Colorado
Outline Preventing & Treating Diabetes Related Blindness Justin Kanoff, MD Eye Care Center of Northern Colorado 303 974 4302 Introduction to Eye Care Center of Northern Colorado How the eye works Eye problems
More informationWhat is Age-Related Macular Degeneration?
Intravitreal Injections Eylea / Lucentis Patient Information What is Age-Related Macular Degeneration? Age-related macular degeneration (AMD) is an eye condition found in older people, which may lead to
More informationFRANZCO, MD, MBBS. Royal Darwin Hospital
Diabetes and Eye By Dr. Nishantha Wijesinghe FRANZCO, MD, MBBS Consultant Ophthalmologist Royal Darwin Hospital 98% of Diabetics do not need to suffer from severe visual loss Yet Diabetic eye disease is
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationDiabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series
Diabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series Joseph J. Pizzimenti, OD, FAAO Associate Professor Nova Southeastern University The Eye Care Institute pizzimen@nova.edu
More informationSerious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist
Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions
More informationDiabetic and the Eye: An Introduction
Diabetic and the Eye: An Introduction Lawrence Iu FRCSEd (Ophth), FCOphthHK, FHKAM (Ophthalmology) Department of Ophthalmology, Grantham Hospital & Queen Mary Hospital Background Diabetes mellitus (DM)
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationParadigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor
Paradigm Shift in the treatment of Diabetic Retinopathy Haytham I. S. Salti, MD Associate Professor Disclosure No financial interests related to the subject matter of this talk This presentation includes
More informationMeasure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Measure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery 2012 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: Percentage
More informationIntravitreal Injection
for patients Eye Clinic Ipswich Hospital Tel: 01473 703230 Intravitreal Injection What is an intravitreal injection? An intravitreal injection is the injection of a drug into the vitreous body (the jelly
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationThe Human Eye. Cornea Iris. Pupil. Lens. Retina
The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in
More informationOcular Pathology. I. Congenital and/or developmental. A. Trisomy 21. Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea)
I. Congenital and/or developmental Robbins Pathologic Basis of Disease, 6 th Ed. A. Trisomy 21 Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea) Focal hypoplasia of iris Cataracts frequently
More informationScott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012
Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser
More informationRetinal Vein Occlusion
Retinal Update 2018 Retinal Vein Occlusion Case Presentations to Myself Branch Vein Occlusion What medical evaluation do you recommend for this 72 year old patient? Is there anything you ask of your medical
More informationPosterior Segment Update
Posterior Segment Update Featured Speaker: Dr. Kyle Cheatham, FAAO, DIP ABO DISCLOSURE STATEMENT We have no direct financial or proprietary interest in any companies, products or services mentioned in
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRetinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationHerpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry
Herpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry I have what?! How to break the news Meet the Herpes Quick virology
More informationImplementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute
Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationImplementing New & Revised ICD-10 Codes
Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates cgreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates
More informationINFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION
INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION INDICATIONS: Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. It is caused by
More informationPreventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country
Diabetes in Indian Country- 2017 Preventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country Albuquerque, NM 20 September2017 Mark B. Horton, OD, MD Director, IHS/JVN Teleophthalmology
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationTreatment of Age Related Macular Degeneration (AMD) by Intravitreal Injection
Information for Patients Manchester Royal Eye Hospital Medical Retina Services Treatment of Age Related Macular Degeneration (AMD) by Intravitreal Injection What is age related macular degeneration (AMD)?
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationMisdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (CSC)
HPTER 12 Misdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (S) linical Features VKH disease is a bilateral granulomatous panuveitis often associated with exudative
More informationChronic eye diseases. Title of section divider. What s new, and how GPs can help. Eg. Case Study 1. Dr Jesse Gale, ophthalmologist
Chronic eye diseases Title of section divider What s new, and how GPs can help Eg. Case Study 1. Dr Jesse Gale, ophthalmologist 1 Title of section divider Cataract Eg. Case Study 1. 2 Cataract - what s
More informationRising to the Challenge of Satisfying Unmet Medical Needs. Back-of-the-eye. Main Back-of-the-Eye Diseases. Uveitis. Behcet s disease.
Feature Rising to the Challenge of Satisfying Unmet Medical Needs Eyeing Further Specialization Back-of-the-eye Diseases Main Back-of-the-Eye Diseases Age-related macular degeneration Uveitis Behcet s
More informationAge-Related Eye Diseases and Conditions. Jonathan M. Frantz, MD, F.A.C.S. Cataract and Refractive Surgeon
Age-Related Eye Diseases and Conditions Jonathan M. Frantz, MD, F.A.C.S. Cataract and Refractive Surgeon Vision Changes Patients notice vision changes with aging. Many changes are common and can often
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationOphthalmology for Primary Care: Do I Really Need to See It? Jennifer R. Olbum, DO
Ophthalmology for Primary Care Jennifer Olbum, DO CCOM 1988 (Midwestern U.) Medical Retina subspecialist jenolbum@aol.com Daniel J. Nadler, MD LLC Beaver, PA Everett & Hurite Ophthalmic Assoc. Belle Vernon,
More informationPresent relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.
Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management
More informationMedical Retina 2011 Nicholas Lee
Medical Retina 2011 Nicholas Lee 1 Diabetic Retinopathy Epidemiology 1000 registered blind each year 2% diabetics registered as blind (8% of all Blind Registrations) 42% with Mild Background DR will progress
More informationDan Roberts. International Low Vision Support Group NEWSLETTER. This Month. In This Issue. 1: This Month 2-5: News
In This Issue 1: This Month 2-5: News Eye & Body Complete from Biosyntrx Extra Strength AREDS-2 Multisupplement Call for information 800-688-6815 The ILVSG is sponsored by MD Foundation www.eyesight.org
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationThe Wilmer Eye Institute s 34 th Annual Current Concepts in Ophthalmology March 13-17, 2017 Vail Marriott * Vail, Colorado
The Wilmer Eye Institute s 34 th Annual Current Concepts in Ophthalmology March 13-17, 2017 Vail Marriott * Vail, Colorado Tentative 1/23/17 PROGRAM MONDAY, MARCH 13, 2017 Morning Session 6:00-7:00 Registration
More informationFront Line Diabetic Retinopathy What Not to Miss and Why
Front Line Diabetic Retinopathy What Not to Miss and Why David M Brown MD FACS Clinical Professor of Ophthalmology Blanton Eye Institute, Houston Methodist Hospital Baylor College of Medicine Retina Consultants
More informationThe Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR
The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences
More informationTreatment of Retinal Vein Occlusion (RVO)
Manchester Royal Eye Hospital Medical Retina Services Information for Patients Treatment of Retinal Vein Occlusion (RVO) What is a Retinal Vein Occlusion (RVO)? The retina is the light sensitive layer
More informationTreatment of wet macular degeneration by intravitreal injection with Ranibizumab (Lucentis) or Aflibercept (Eylea): Information and consent
Patient information Treatment of wet macular degeneration by intravitreal injection with Ranibizumab (Lucentis) or Aflibercept (Eylea): Information and consent Introduction You have an eye condition called
More informationCURRENT RESEARCH ACTIVITIES AT LOMA LINDA EYE INSTITUTE. David Sierpina, MD Assistant Professor Medical Retina and Comprehensive Ophthalmology
CURRENT RESEARCH ACTIVITIES AT LOMA LINDA EYE INSTITUTE David Sierpina, MD Assistant Professor Medical Retina and Comprehensive Ophthalmology CONFLICTS OF INTEREST No financial conflicts of interest to
More informationROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS
ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,
More informationWest Los Angeles VA Health Care Center
West Los Angeles VA Health Care Center A review of the demographics of a group of general optometry patients seen recently (2015) at the main eye clinic in bldg. 304 yielded the following: Age range: 33-75
More informationOptometry Student Extern Manual. Miami VA Medical Center
Optometry Student Extern Manual Miami VA Medical Center Table of contents: Rotation Description 3 Clinic Schedules 4 Absences 4 Performance Standards 5 When to check in with attending 5 References 6 Visual
More informationVenous Occlusive Diseases
Venous Occlusive Diseases Bruce R. Saran, MD Adjunct Assistant Clinical Professor of Medicine Scheie Eye Institute University of Pennsylvania School of Medicine Philadelphia, PA -a division of: RVO Demographics
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationDrug Class Update: Vascular Endothelial Growth Factors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Foundation WHAT IS THE RETINA?
Age-Related Macular Degeneration (AMD) is a deterioration of the retina and choroid that leads to a substantial loss in visual acuity (sharpness of vision). AMD is the leading cause of significant visual
More informationAge-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) What is the Macula? What is Dry AMD (Age-related Macular Degeneration)? Dry AMD is an aging process that causes accumulation of waste product under the macula leading
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationEyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD
EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina Retinal Arcades Macula Optic
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationPRECISION PROGRAM. Injection Technique Quick-Reference Guide. Companion booklet for the Video Guide to Injection Technique
Injection Technique Quick-Reference Guide PRECISION PROGRAM Companion booklet for the Video Guide to Injection Technique Available at www.ozurdexprecisionprogram.com Provides step-by-step directions with
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More informationGlaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?
Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the
More informationevaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography
evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD
More informationRecalcitrant Diabetic Macular Oedema: Therapeutic Options
December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan
More informationPrevention and treatment of agerelated macular degeneration
THERAPY REVIEW Prevention and treatment of agerelated macular degeneration SARAH HORTON AND CATHERINE GULY Age-related macular degeneration (AMD) is a common cause of visual loss in older people and GPs
More information10 EYE EMERGENCIES. Who goes, who you better not send! Brant Slomovic, MD, FRCPC University Health Network
10 EYE EMERGENCIES Who goes, who you better not send! Brant Slomovic, MD, FRCPC University Health Network DISCLOSURES I have none PVD CASE 1 WHAT IS A PVD? a process of aging (45-55) liquefaction of vitreous
More informationNEPTUNE RED BANK BRICK
NEPTUNE RED BANK BRICK Diabetes & The Eye Diabetics are more likely to develop Cataracts at a younger age. Diabetics are twice as likely to develop Glaucoma when compared to non-diabetics. The primary
More informationDr. D. Y. Patil Medical College, Pimpri, Pune
Dr. D. Y. Patil Medical College, Pimpri, Pune - 411 018 Period : 04/July/16 to 22/September/16 Semester : 7 th Semester Department : Ophthalmology Lecture Lesson Plan Sr No Date Topic Learning objectives
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationRetinal Diseases. Age-Related Macular Degeneration. What Is AMD? Risk Factors for AMD
Santosh C. Patel, M.D. Retina Specialists The Latest And Greatest in the Management of Retinal Diseases February 13, 2007 Retinal Diseases Majority of Blindness in Civilized World AMD Diabetic Retinopathy
More informationOphthalmology. Juliette Stenz, MD
Ophthalmology Juliette Stenz, MD Required Slide Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Required Slide At the end of this session, students will be able to: 1.
More information